Stock ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Oncolytics Biotech Inc. Nasdaq

Equities

CA6823101077

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
AQ
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
MT
Oncolytics Biotech Announces Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program
CI
Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
MT
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
CI
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX
MT
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
MT
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
PR
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer
MT
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
AQ
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR
Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. Stock
  5. News Oncolytics Biotech Inc.